DOI: https://doi.org/10.21203/rs.3.rs-129834/v1
Background
Bone metastases (BM) represents a common complication of cancer, patients with BM may experience skeletal complications, such as pathological fractures, spinal cord compression, hypercalcemia, and persisting pain. Currently, there are a large number of publications available on this topic. The purpose of this study was to identify and analyze the 100 most-cited publications on BM research.
Method
All databases from the Web of Science were searched in a three-step approach. First, the 100 most-cited BM studies were identified using only one term “bone metastases” to allow for comprehensive keyword identification. Second, ten keywords identified from the results of the first search were used to conduct a second search of the databases to yield a separate list of the top 100 cited BM publications. Finally, the results of the two searches were overlapped and duplicated articles were removed. After overlapping, the top 100 most-cited articles on BM were selected for further analysis of title, authorship, source journal, publication year, geographic origin, research institution, number of citations, and subspecialty.
Results
The 100 most-cited articles were published from 1959 to 2014 in 44 different journals and were cited from 250 to 1707 times. The most influential period was from 2001–2010, which produced 50 out of the top 100 publications. A total of 12 countries contributed to the 100 articles, and the United States topped the list with 48 articles. The majority of publications were in Journal of Clinical Oncology, which published 16 articles. In terms of institutional support, a total of 13 institutions each supported at least 2 articles, and the first ranked institution was University of Texas M. D. Anderson Cancer Center (USA) with 8 articles. Regarding subspecialty of the studies, the most frequent studies were “clinical description” with 30 articles, followed by “clinical trial” with 20 articles.
Conclusion
In this comprehensive review, we identified and analyzed the 100-most-cited articles on BM research by measuring their citation number, and recognized some of the most important contributions by authors, institutions and countries. Furthermore, our study will help researchers and orthopedic surgeons understand the research trends for BM and as an efficient guide for future BM-related research.
Bone metastases (BM) represents a common complication in the most prevalent human cancers, whose incidence reaches 70–95% in multiple myeloma (MM), up to 65–90% in prostate cancer (PC), 65–75% in breast cancer (BC), 17–64% in lung cancer (LC), and 10% in colorectal cancer (CC) [1-4]. Patients with BM may experience skeletal complications including pathological fractures, hypercalcemia, spinal cord and nerve compression syndromes, and uncontrolled pain that require orthopedic surgery or/and radiotherapy, collectively referred to as skeletal-related events (SREs) [5,6]. These events seriously affect the quality of life (QoL) of patients and patient survival rates [7]. Therefore, the major treatment options for BM patients aim at improving the QoL and reducing SREs. Currently, BM treatments include loco-regional and systemic approaches. The former, mainly represented by focal excision and radiotherapy, are usually performed to relieve bone pain and to prevent pathological fractures. The latter mainly include anabolic agents, inhibitors of bone resorption and radiopharmaceuticals that aim at restoring severely impaired physiological bone turnover in metastatic bone disease patients [8].
In recent years, with the emergence of imaging techniques with improved sensitivity and specificity in the detection of bone injury, the early diagnosis of BM has significantly improved [9]. The diagnosis and management of BM has also gained much interest among surgeons, similarly, fundamental scientific research has also made major breakthroughs in understanding the mechanism involved in the development of BM. Concomitantly, a large number of studies regarding BM have been published.
Bibliometric analysis is a widely accepted approach for identifying high impact scientific studies on medicine and to quantitatively and qualitatively evaluate its academic impact [10,11] This analysis method has been widely performed in the field of orthopedic surgery [12-16]. To the best of our knowledge, there have been no reports on bibliometric analysis on BM to date. Therefore, our objective was to identify the top 100 most-cited studies on BM, and to analyze the characteristics and research trends of the most impactful publications. This bibliographic analysis will augment efforts in research consensus and will enable researchers to better align their research direction to address the issues that require additional research due to the lack of evidence and to tailor their future research on BM.
Inclusion Criteria
All available journals from the Web of Science database were searched to identify and analyze the 100 most-cited articles on BM between 1950 and 2020. To be considered for the top 100 list: (1) papers had to focus on the field of BM; (2) papers should be written in English; and (3) the publication date should be between the 1950 and 2020.
Exclusion Criteria
The exclusion criteria included: (1) papers that focused on broad areas with no emphasis on BM; and (2) papers focused on primary bone/spinal tumor.
Search strategy and study selection
As of 5 July 2020, we identified the 100 most-cited BM research studies published between 1950 and 2020, excluding non-English language studies. In order to achieve a higher comprehensiveness and accurateness of the study, a three-step approach was adopted to search the databases of the Web of Science, as shown in the flow chart in Figure 1.
First, the Web of Science databases was searched using the keyword “bone metastases.” The search produced 85,957 results, which were then ranked in descending order of the total number of citations. In the initial 1200 studies identified, the 100 most-cited papers on BM were selected based on titles and abstracts. The aim was to provide a more comprehensive study of BM, and the title and abstract of the identified 100 studies were systematically analyzed for possible keywords. Combined with other keywords known to be relevant to the field of BM research, a search query composed of a group of 10 keywords was established and used for a second database search by topic. The 10 keywords identified were “bone metastases,” “bone metastasis,” “metastatic bone disease,” “skeletal metastases,” “spinal metastases,” “spinal metastasis,” “metastatic spine disease,” “osseous metastases,” “osteolytic metastases,” and “osteoblastic metastases.”
Second, every search word or phrase was delimited by an OR term, by this means, additional search results were obtained. The second search showed 105,159 results, again were ranked these in descending order of the total number of citations. Of the top 1000 preliminary studies, 100 articles related to BM were selected based on titles and abstracts.
Third, the studies of the two selections were compared, and duplicate studies were removed and the 100 most-cited BM studies were selected for finally analysis.
To ensure consistency of data extraction, two independent authors evaluated the articles for their relevance to BM and the 100 most-cited articles on BM were finial determined. Finally, the 100 most-cited articles were then extracted with regard to basic information including: title, authorship, source journal, publication year, geographic origin, research institution, number of citations, and subspecialty.
Statistical Methods
All data were manually extracted from the Web of Science database and recorded in Microsoft Excel 2016 or further analysis or visualization. VOSviewer (Leiden University, Leiden, the Netherlands) is a commonly used software tool for creating maps for network analysis and visualization. In this study, this software was used to visualize the relationships and the time distribution between the most frequently occurring concepts and keywords.
Overview of publications
The 100 most-cited articles involving BM research were cited from 250 to 1707 times in 44 different journals and the mean citation number was 467.5 (Table 1). “A multigenic program mediating breast cancer metastasis to bone,” published by Kang et al., was the most-cited article (cited 1707 times). The earliest published article was “Experiences with metastatic neoplasms involving the spinal cord,” which was published in 1959 by Barron et al. (cited 312 times). The most recent article was “Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial,” published by Sartor et al. in 2017 (cited 312 times).
Country of publications
The top 100 articles originated from 12 different countries. Authors from the United States contributed 48 articles. European centers from ten countries published 34 articles in total. Among these, 10 articles were from the United Kingdom, 8 articles were from France, 3 articles were from Italy, Sweden, and The Netherlands, 2 articles were from Switzerland and Belgium, and 1 article was from Austria, Denmark and Germany. Authors from Asia and Africa published relatively fewer articles compared to the United States and Europe. Authors from Japan published 5 articles, and Israel 1 articles, respectively. Besides, authors from Canada and Australia published 10 and 1 articles, respectively.
Year of publication
The publishing period responsible for the largest number of studies was 2001 to 2010 with 50 articles, followed by 1991 to 2000 with 24 articles, 1981 to 1990 with 11 articles, 2011 to 2014 with 10 articles, and the period 1971 to 1980 with 3 articles (Figure 3). Notably, only 2 articles were published before 1970.
Journals of publications
Overall, 44 different journals were represented on the list of the 100 most-cited studies (Table 2). The Journal of Clinical Oncology was the most popular journal, which was responsible for 16 articles and 7218 total citations. This was followed by Cancer with 10 articles with 4888 total citations. Cancer Research, Spine, Journal of Neurosurgery, Journal of the National Cancer Institute, and Cancer Cell each with 4, 4, 3, 3 and 3 articles, respectively. Although there were only 2 articles on the list which were published in Lancet, their mean citations per article was the highest (1106 times per article).
Authors of publications
Regarding the authors, A Lipton was the most productive author with 11 articles in total, followed by R. E. Coleman with 11 articles. J. E. Brown, G. N. Hortobagyi, F. Saad, J. J. Seaman, J. J. Body, and L. S. Rosen, with 5 articles each (Table 3).
Institutions of publications
In terms of institutional support, a total of 13 institutions each supported at least 2 articles (Table 4). The first ranked institution was the University of Texas M. D. Anderson Cancer Center (USA) with 8 articles. The second top ranked institution was Weston Park Hospital with 5 articles. The Memorial Sloan-Kettering Cancer Center (USA), and the University of Toronto (Canada) were tied for third with 4 articles each.
Subspecialty of publications
Regarding the subspecialty of the studies, the most frequent studies were “clinical description” (n=30), followed by “clinical trial” (n=20), “mechanism” (n=16), “drug efficacy” (n=11) “radiotherapy” (n=7), “evaluation” (n=5), “surgery treatment” (n=4), “detection” (n=3), “murine model” (n=2), and “prediction” (n=2) (Figure 4).
Keyword analysis of publications
As shown in Figure 5, the 28 terms (defined as being used more than 6 times within titles and abstracts in all of the articles) were classified into 3 clusters: “clinical trial”, “clinical features”, and “basic research”. Among the “clinical trial” cluster, keywords used in the top articles were listed as follows: trial (30 items), time (26 items), event (23 items), week (22 items), and spinal cord compression (20 items). For the cluster of “clinical features”, the primary keywords were as follows: treatment (61 items), survival (29 items), pain (29 items), year (27 items), and site (21 items). In the “basic research” cluster, the primary keywords were as follows: cell (35 items), factor (25 items), breast cancer (25 items), effect (24 items), and therapy (22 items).
As shown in Figure 6, VOSViewer assigned colors to keywords according to the average year in which they appeared in the article. In the early stage of BM research, both the biological and clinical fields were the main hotspots. In the early stage of BM research, treatment of BM was the main hotspot. Recent trends showed that the words “SRE”, “zoledronic acid”, “hazard rate”, “denosumab”, and “intension” appeared as keywords articles after 2006. There was most of the key words appear in the “clinical trial” cluster.
The present bibliometric analysis determined and characterized the 100 most-cited publications in the Web of Science databases. After identifying the most-cited research articles, we obtained insight into the historic developmental trends in BM research that reflected the great importance and academic concern placed on the study of BM.
Undoubtedly the publishing date will affect citation numbers, the longer periods after the article is published allows for a greater opportunity to be cited. In our study, the most productive period was from 2001 to 2010 with 50 articles. However, only 2 articles were published before 1970. This indicates that the improvement of BM research quality and efficiency promoted an increase in papers and citations in recent years. Notably, no top-cited articles were published after 2015 in our current analysis. We speculated the following possible reasons for this: firstly, because BM has always been a hot research field for researchers and orthopedic surgeons, numerous high-quality articles have already been published, although, we have only included the top 100 most-cited articles, therefore, articles with relatively fewer citations are not included. Secondly, more recently published articles need time to be cited widely.
In total, 44 different journals published the top 100 most-cited studies, with the Journal of Clinical Oncology contributing most studies, followed by Cancer. It has been reported that major journals can attract high-quality research articles in their fields, maintaining high the impact factors of these journals [17]. Compared with other similar bibliometric studies, top 100 articles have been published in a greater number of journals, while, the most contributive journals have published fewer articles [18,19]. We speculated that this may be related to more high-quality journals in the field of cancer.
Overall, 12 different countries contributed to the top 100 articles, and the most productive country of article origin was the United States, followed by European centers. In contrast, Asia (Japan, Israel) made a relatively small contribution to the 100 most-cited articles, which indicated that there is still a large gap of scientific studies published between Asian countries and western developed areas. Thus, various countries, especially in developing regions, have to endeavor make greater contributions to be integrated into the world scientific processes.
VOSviewer software was used to analyze the keywords of the main subjects of these 100 articles. The 100 most-cited articles extracted from all database of the Web of Science were classified into 3 clusters: “clinical trial,” “clinical features,” and “basic research.” In the clinical trial cluster, “trial” and “time” were the most frequently appearing keywords on the network map. This finding demonstrated that randomized controlled trials investigating drug therapy are a major research direction in the field of BM. In the clinical features cluster, the most frequently occurring keywords included “treatment,” “survival,” and “pain” meaning that the clinical efficacy and prognosis of BM patients have been widely studied. Further, in the basic research cluster, “cell,” “factor,” and “breast cancer” were the most frequently keywords, which illustrated that the research interest was mainly focused on the molecular biology of BM. Generally, molecular mechanisms, treatment, and prognosis were hot topics in the research of BM.
Keyword analysis is an indispensable approach to evaluate the evolution of research hotspots in this field. To the best of our knowledge, this study is the first to visually summarize the evolution of global research trends on BM. Among the 3 keyword clusters “clinical trial,” “clinical features,” and “basic research,” the former is of great interest because of the obvious changes in the research hotspots over the last 20 years. From simple attention to pain control to a series of clinical problems caused by SREs, researchers and surgeons are focusing increasingly on improving prognosis and prolonging the survival of patients with BM [20,21]. In-depth study of the molecular mechanisms, targeted therapies, and immunotherapy have attracted increasing attention, and some studies have led to agents being recommended as first-line drugs by the guidelines, such as denosumab [22]. In addition, in recent years, with the rapid progress of radiotherapy research, especially the emergence of stereotactic body radiation therapy (SBRT), radiotherapy has also received strong research interest from doctors and patients [23,24]. Even so, surgery and chemotherapy still play an irreplaceable role. Thus, it is necessary to review the highly quality articles to understand milestones during the study of BM.
Although this current analysis was relatively comprehensive and objective, it had several limitations. First, the date for literature search was 5 July 2020, theoretically, which could limit the citation numbers by time. Second, besides the Web of Science, Google Scholar and SCOPUS databases could also provide citation data, these databases may display a different number of citations and therefore may provide different analysis results [25].Third, since the top 100 articles selected are limited to English, we might have overlooked high-impact articles in other languages. Finally, some recently published high-quality articles were not included in this analysis due to their low citation frequency.
In summary, despite its limitations, bibliometric analysis remains one of the best methods to quantify the impact of scientific studies and to quantify the contributions of researchers [26,27]. We believe that this study highlights a series of intellectual milestones in BM research. The present study identified influential authors, institutions, countries, and journals that have made outstanding contributions to BM research. Undoubtedly, this study will provide a catalogue of valuable articles for young researchers and will help scientists to master research hotspots and to determined future academic pursuits.
The BM literature has grown continuously over the years. The 100 most-cited publications in BM research were searched and analyzed, and the contribution of the authors and their origins were identified. This article provides insight into the development of BM research, and should contribute to help scientists to grasp the international research hotspots on BM research.
BM: bone metastases
MM: multiple myeloma
PC: prostate cancer
BC: breast cancer
LC: lung cancer
CC: colorectal cancer
SREs: skeletal-related events
QoL: quality of life
SBRT: stereotactic body radiation therapy
Acknowledgements
Not applicable.
Author’s contributions
Conceived and designed the study: Yao Kang and Jun Zhang. Revised the protocol: Tingxiao Zhao and Yuan Zhang. Extracted the data: Jun Lv, Meng Ge and Yazeng Huang. Performed the statistical analysis: Zhanqiu Dai, Haiyu Shao, and Xiaoyan Ding. Wrote the manuscript: Tingxiao Zhao and Yuan Zhang. All authors contributed constructive comments on the paper. The authors read and approved the final manuscript.
Funding
This study was supported by grants from The Graduate Research and Innovation Program of Bengbu Medical College (Byycx1906 to Dr. Tingxiao Zhao ).
Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
Ethics approval is not required due to this work is carried out on open data.
Consent for publication
Not applicable.
Competing Interests:
The authors declare that they have no competing interests.
Device Status/Drug Statement:
The manuscript submitted does not contain information about medical devices
TABLE 1. The Top 100 Cited Articles on Bone Metastases |
||||||
Rank |
Author |
Title |
Journal |
Year |
Citation |
Citation No./Year |
1 |
Kang, Y. B. |
A multigenic program mediating breast cancer metastasis to bone |
Cancer Cell |
2003 |
1707 |
100.41 |
2 |
Roodman, G. D. |
Mechanisms of disease: mechanisms of bone metastasis |
New England Journal of Medicine |
2004 |
1347 |
84.19 |
3 |
Coleman, R. E. |
Clinical features of metastatic bone disease and risk of skeletal morbidity |
Clinical Cancer Research |
2006 |
1122 |
80.14 |
4 |
Patchell, R. A. |
Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial |
Lancet |
2005 |
1115 |
74.33 |
5 |
Fizazi, K. |
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study |
Lancet |
2011 |
1097 |
121.89 |
6 |
Coleman, R. E |
Metastatic bone disease: clinical features, pathophysiology and treatment strategies |
Cancer Treatment Reviews |
2001 |
1048 |
55.16 |
7 |
Coleman, R. E. |
Skeletal complications of malignancy |
Cancer |
1997 |
1011 |
43.96 |
8 |
Stopeck, A. T. |
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study |
Journal of Clinical Oncology |
2010 |
839 |
83.90 |
9 |
Saad, F. |
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer |
Journal of the National Cancer Institute |
2004 |
784 |
49.00 |
10 |
Taichman, R. S. |
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone |
Cancer Research |
2002 |
761 |
42.28 |
11 |
Coleman, R. E. |
The clinical course of bone metastases from breast cancer |
British Journal of Cancer |
1987 |
755 |
22.88 |
12 |
Hortobagyi, G. N. |
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group |
The New England Journal of Medicine |
1996 |
746 |
31.08 |
13 |
Yin, J. J. |
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development |
Journal of Clinical Investigation |
1999 |
692 |
32.95 |
14 |
Hillner, B. E. |
American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer |
Journal of Clinical Oncology |
2003 |
688 |
40.47 |
15 |
Tomita, K. |
Surgical strategy for spinal metastases |
Spine |
2001 |
642 |
33.79 |
16 |
Gilbert, R. W. |
Epidural spinal cord compression from metastatic tumor: diagnosis and treatment |
Annals of Neurology |
1978 |
637 |
15.17 |
17 |
Henry, D. H. |
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma |
Journal of Clinical Oncology |
2011 |
631 |
70.11 |
18 |
Rosen, L. S. |
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial |
Cancer Journal |
2001 |
618 |
32.53 |
19 |
Cotten, A. |
Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methyl methacrylate at clinical follow-up |
Radiology |
1996 |
615 |
25.63 |
20 |
Rosen, L. S. |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trialarative trial |
Cancer |
2003 |
595 |
35.00 |
21 |
Weilbaecher, K. N. |
Cancer to bone: a fatal attraction |
Nature Reviews Cancer |
2011 |
577 |
64.11 |
22 |
Thalmann, G. N. |
Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer |
Cancer Research |
1994 |
560 |
21.54 |
23 |
Fleisch, H. |
Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease |
Drugs |
1991 |
558 |
19.24 |
24 |
Mercadante, S. |
Malignant bone pain: pathophysiology and treatment |
Pain |
1997 |
553 |
24.04 |
25 |
Tong, D. |
The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group |
Cancer |
1982 |
537 |
14.13 |
26 |
Weill, A. |
Spinal metastases: indications for and results of percutaneous injection of acrylic surgical cement |
Radiology |
1996 |
524 |
21.83 |
27 |
Tokuhashi, Y. |
A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis |
Spine |
2005 |
520 |
34.67 |
28 |
Even-Sapir, E. |
The detection of bone metastases in patients with high-risk prostate cancer: Tc-99m-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, F-18-fluoride PET, and F-18-fluoride PET/CT |
Journal of Nuclear Medicine |
2006 |
518 |
37.00 |
29 |
Jones, D. H. |
Regulation of cancer cell migration and bone metastasis by RANKL |
Nature |
2006 |
500 |
35.71 |
30 |
Chow, E. |
Palliative radiotherapy trials for bone metastases: A systematic review |
Journal of Clinical Oncology |
2007 |
497 |
38.23 |
31 |
Boissier, S. |
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases |
Cancer Research |
2000 |
482 |
24.10 |
32 |
Rosen, L. S. |
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The zoledronic acid lung cancer and other solid tumors study group |
Journal of Clinical Oncology |
2003 |
473 |
27.82 |
33 |
Lutz, S. |
Palliative radiotherapy for bone metastases: an astro evidence-based guideline |
International Journal of Radiation Oncology Biology Physics |
2011 |
473 |
52.56 |
34 |
Lipton, A. |
Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases - Long term follow-up of two randomized, placebo-controlled trials |
Cancer |
2000 |
469 |
23.45 |
35 |
Soloway, M. S. |
Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan |
Cancer |
1988 |
459 |
14.34 |
36 |
Fourney, D. R. |
Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients |
Journal of Neurosurgery |
2003 |
453 |
26.65 |
37 |
Hortobagyi, G. N. |
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group |
Journal of Clinical Oncology |
1998 |
445 |
20.23 |
38 |
Theriault, R. L. |
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial |
Journal of Clinical Oncology |
1999 |
439 |
20.90 |
39 |
Hartsell, W. F. |
Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases |
Jnci-Journal of the National Cancer Institute |
2005 |
438 |
29.20 |
40 |
Gerszten, P. C. |
Radiosurgery for spinal metastases - Clinical experience in 500 cases from a single institution |
Spine |
2007 |
438 |
33.69 |
41 |
Paterson, A. H. |
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer |
Journal of Clinical Oncology |
1993 |
437 |
16.19 |
42 |
Rosen, L. S. |
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors - A randomized, phase III, double-blind, placebo-controlled trial |
Cancer |
2004 |
434 |
27.13 |
43 |
Zhang, X. H. |
Latent bone metastasis in breast cancer tied to src-dependent survival signals |
Cancer Cell |
2009 |
424 |
38.55 |
44 |
Mundy, G. R. |
Mechanisms of bone metastasis |
Cancer |
1997 |
413 |
17.96 |
45 |
Steenland, E. |
The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study |
Radiotherapy and Oncology |
1999 |
411 |
19.57 |
46 |
Schlumberger, M. |
Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma |
The Journal of Clinical Endocrinology and Metabolism |
1986 |
406 |
11.94 |
47 |
Brown, J. E. |
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors |
Jnci-Journal of the National Cancer Institute |
2005 |
392 |
26.13 |
48 |
Coleman, R. E. |
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid |
Journal of Clinical Oncology |
2005 |
379 |
25.27 |
49 |
Kang, Y. B. |
Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway |
Proceedings of the National Academy of Sciences of the United States of America |
2005 |
370 |
24.67 |
50 |
Tokuhashi, Y. |
Scoring system for the preoperative evaluation of metastatic spine tumor prognosis |
Spine |
1990 |
367 |
12.23 |
51 |
Cook, G. J. |
Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions |
Journal of Clinical Oncology |
1998 |
361 |
16.41 |
52 |
Fizazi, K. |
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates |
Journal of Clinical Oncology |
2009 |
359 |
32.64 |
53 |
Berenson, J. R. |
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. A double-blind, randomized dose-response study |
Cancer |
2001 |
353 |
18.58 |
54 |
Goetz, M. P. |
Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study |
Journal of Clinical Oncology |
2004 |
352 |
22.00 |
55 |
Logothetis, C. J. |
Osteoblasts in prostate cancer metastasis to bone |
Nature Reviews Cancer |
2005 |
352 |
23.47 |
56 |
Wu, J. S. Y. |
Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases |
International Journal of Radiation Oncology Biology Physics |
2003 |
350 |
20.59 |
57 |
Nielsen, O. S. |
Bone metastases: pathophysiology and management policy |
Journal of Clinical Oncology |
1991 |
349 |
12.03 |
58 |
Saad, F. |
Pathologic fractures correlate with reduced survival in patients with malignant bone disease |
Cancer |
2007 |
346 |
26.62 |
59 |
Sasaki, A. |
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice |
Cancer research |
1995 |
344 |
13.76 |
60 |
Kohno, N. |
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial |
Journal of Clinical Oncology |
2005 |
343 |
22.87 |
61 |
Body, J. J. |
A study of the biological receptor activator of nuclear factor-kappa B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer |
Clinical Cancer Research |
2006 |
341 |
24.36 |
62 |
Nilsson, S. |
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study |
Lancet Oncology |
2007 |
339 |
26.08 |
63 |
Young, R. F. |
Treatment of spinal epidural metastases. Randomized prospective comparison of laminectomy and radiotherapy |
Journal of neurosurgery |
1980 |
339 |
8.48 |
64 |
Fisher, C. G. |
A novel classification system for spinal instability in neoplastic disease an evidence-based approach and expert consensus from the Spine Oncology Study Group |
Spine |
2010 |
337 |
33.70 |
65 |
Schlumberger, M. |
Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma |
Journal of Nuclear Medicine |
1996 |
336 |
14.00 |
66 |
Hamaoka, T. |
Bone imaging in metastatic breast cancer |
Journal of Clinical Oncology |
2004 |
336 |
21.00 |
67 |
Price, P. |
Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases |
Radiotherapy and Oncology |
1986 |
333 |
9.79 |
68 |
Saad, F. |
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases |
Annals of Oncology |
2012 |
323 |
40.38 |
69 |
Mirels, H. |
Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures |
Clinical Orthopaedics and Related Research |
1989 |
321 |
10.35 |
70 |
Guise, T. A. |
Basic mechanisms responsible for osteolytic and osteoblastic bone metastases |
Clinical Cancer Research |
2006 |
318 |
22.71 |
71 |
Yamada, Y. |
High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions |
International Journal of Radiation Oncology Biology Physics |
2008 |
315 |
26.25 |
72 |
Chow, E. |
Update on the systematic review of palliative radiotherapy trials for bone metastases |
Clinical Oncology |
2012 |
312 |
39.00 |
73 |
Barron, K. D. |
Experiences with metastatic neoplasms involving the spinal cord |
Neurology |
1959 |
312 |
5.11 |
74 |
Sethi, N. |
Tumor-derived jagged1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells |
Cancer Cell |
2011 |
310 |
34.44 |
75 |
Body, J. J. |
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases |
Annals of Oncology |
2003 |
307 |
18.06 |
76 |
Maranzano, E. |
Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial |
International Journal of Radiation Oncology, Biology, Physics |
1995 |
307 |
12.28 |
77 |
Takeshita, F. |
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo |
Proceedings of the National Academy of Sciences of the United States of America |
2005 |
306 |
20.40 |
78 |
Chang, E. L. |
Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure |
Journal of Neurosurgery-Spine |
2007 |
304 |
23.38 |
79 |
Boucharaba, A. |
Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer |
Journal of Clinical Investigation |
2004 |
300 |
18.75 |
80 |
Wong, D. A. |
Spinal metastases: the obvious, the occult, and the impostors |
Spine |
1990 |
299 |
9.97 |
81 |
Hornberg, E. |
Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival |
Plos One |
2011 |
296 |
32.89 |
82 |
Lipton, A. |
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials |
European Journal of Cancer |
2012 |
290 |
36.25 |
83 |
Serafini, A. N. |
Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial |
Journal of Clinical Oncology |
1998 |
290 |
13.18 |
84 |
Kingsley, L. A. |
Molecular biology of bone metastasis |
Molecular Cancer Therapeutics |
2007 |
286 |
22.00 |
85 |
Arguello, F. |
A murine model of experimental metastasis to bone and bone marrow |
Cancer Research |
1988 |
286 |
8.94 |
86 |
Gu, Z. |
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer |
Oncogene |
2000 |
281 |
14.05 |
87 |
Constans, J. P. |
Spinal metastases with neurological manifestations. Review of 600 cases |
Journal of Neurosurgery |
1983 |
280 |
7.57 |
88 |
Daldrup-Link, H. E. |
Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET |
American Journal of Roentgenology |
2001 |
275 |
14.47 |
89 |
Nilsson, S. |
First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases |
Clinical Cancer Research |
2005 |
273 |
18.20 |
90 |
Chen, T. L. |
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases |
Journal of Clinical Pharmacology |
2002 |
273 |
15.17 |
91 |
Body, J. J. |
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases |
Cancer |
2003 |
271 |
15.94 |
92 |
Bendre, M. S. |
Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease |
Bone |
2003 |
270 |
15.88 |
93 |
Deckers, M. |
The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells |
Cancer Research |
2006 |
268 |
19.14 |
94 |
Sartor, O. |
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial |
Lancet Oncology |
2014 |
264 |
44.00 |
95 |
Thalmann, G. N. |
LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis |
Prostate |
2000 |
263 |
13.15 |
96 |
Galasko, C. S. |
Mechanisms of bone destruction in the development of skeletal metastases |
Nature |
1976 |
262 |
5.95 |
97 |
Murray, L. J. |
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model |
Clinical & Experimental Metastasis |
2003 |
259 |
15.24 |
98 |
Edelstyn, G. A. |
The radiological demonstration of osseous metastases. Experimental observations |
Clinical Radiology |
1967 |
259 |
4.89 |
99 |
Lelekakis, M. |
A novel orthotopic model of breast cancer metastasis to bone |
Clinical & Experimental Metastasis |
1999 |
257 |
12.24 |
100 |
Jacobs, S. C. |
Spread of prostatic cancer to bone |
Urology |
1983 |
250 |
6.76 |
TABLE 2. Publishing Years of the Top 100 Cited Articles on Bone Metastases |
|||
Publishing Years |
Articles |
Total Citations |
Mean Citations |
1959 |
1 |
312 |
312 |
1967 |
1 |
259 |
259 |
1971-1980 |
3 |
1238 |
412.67 |
1981-1990 |
11 |
4293 |
390.27 |
1991-2000 |
24 |
11143 |
464.29 |
2001-2010 |
50 |
24935 |
498.7 |
2011-2014 |
10 |
4573 |
457.3 |
TABLE 3. Journals with More Than One of the Top 100 Cited Articles on Bone Metastases |
||||
Journals |
Articles |
Total Citations |
Mean Citations |
Impact Factor |
Journal of Clinical Oncology |
16 |
7218 |
451.13 |
32.956 |
Cancer |
10 |
4888 |
488.8 |
5.742 |
Cancer research |
6 |
2701 |
450.17 |
9.727 |
Spine |
6 |
2603 |
433.83 |
2.646 |
Clinical Cancer Research |
4 |
2054 |
513.5 |
10.107 |
International Journal of Radiation Oncology Biology Physics |
4 |
1445 |
361.25 |
5.859 |
Journal of Neurosurgery |
3 |
1072 |
357.33 |
3.968 |
Cancer Cell |
3 |
2441 |
813.67 |
26.602 |
Annals of Oncology |
2 |
630 |
315 |
18.274 |
Clinical & Experimental Metastasis |
2 |
516 |
258 |
3.037 |
Journal of the National Cancer Institute |
2 |
830 |
415 |
11.577 |
Journal of Clinical Investigation |
2 |
992 |
496 |
11.864 |
Journal of Nuclear Medicine |
2 |
854 |
427 |
7.887 |
Lancet |
2 |
2212 |
1106 |
60.392 |
Lancet Oncology |
2 |
603 |
301.5 |
33.752 |
Nature |
2 |
762 |
281 |
42.778 |
Nature Reviews Cancer |
2 |
929 |
464.5 |
53.03 |
Proceedings of the National Academy of Sciences of the United States of America |
2 |
676 |
338 |
9.412 |
Radiology |
2 |
1139 |
569.5 |
7.931 |
Radiotherapy and Oncology |
2 |
744 |
372 |
4.856 |
TABLE 4. Most Frequent Authors of the 100 Most Cited Articles on Bone Metastases |
|||||
Authors |
Articles |
First Author |
Last Author |
Coauthor |
Areas of Interest |
Lipton, A. |
13 |
2 |
0 |
11 |
Drug efficacy; Clinical trial; Prediction |
Coleman, R. E. |
11 |
5 |
2 |
4 |
Drug efficacy; Clinical trial; Prediction |
Brown, J. E. |
5 |
1 |
0 |
4 |
Clinical trial; Prediction |
Hortobagyi, G. N. |
5 |
2 |
0 |
3 |
Drug efficacy; Clinical trial; Clinical description |
Saad, F. |
5 |
3 |
0 |
2 |
Drug efficacy; Prediction |
Seaman, J. J. |
5 |
0 |
3 |
2 |
Clinical trial |
Body, J. J. |
5 |
3 |
0 |
2 |
Drug efficacy; Prediction |
Rosen, L. S. |
5 |
4 |
0 |
1 |
Clinical trial |
Dansey, R. |
4 |
0 |
1 |
3 |
Clinical trial; Clinical description |
Fizazi, K. |
4 |
2 |
0 |
2 |
Clinical trial; Clinical description |
Gordon, D. |
4 |
0 |
0 |
4 |
Clinical trial |
Guise, T. A. |
4 |
1 |
1 |
2 |
Mechanism |
Jun, S. |
4 |
0 |
2 |
2 |
Clinical trial |
Theriault, R. L. |
4 |
1 |
0 |
3 |
Drug efficacy; Clinical trial |
TABLE 5. Contributing Institutions with More Than Two of the Top 100 Cited Articles on Bone Metastases |
|||
Institutions |
Location |
Articles |
Total Citations |
University of Texas M. D. Anderson Cancer Center |
USA |
8 |
3635 |
Weston Park Hospital |
United Kingdom |
5 |
4328 |
Memorial Sloan-Kettering Cancer Center |
USA |
4 |
2816 |
University of Toronto |
Canada |
4 |
1745 |
Cancer Institute Medical Group |
USA |
3 |
1502 |
University of California |
USA |
3 |
1238 |
University of Texas Health Science Center at San Antonio |
USA |
3 |
1449 |
Centre Hospitalier de l'Université de Montréal |
Canada |
2 |
1130 |
Institut Jules Bordet |
Belgium |
2 |
612 |
Joan Karnell Cancer Center |
USA |
2 |
735 |
Nihon University |
Japan |
2 |
887 |
University of Berne |
Switzerland |
2 |
821 |
University of Virginia |
USA |
2 |
604 |